Topline results were announced from a phase 3 trial evaluating solriamfetol for the treatment of major depressive disorder (MDD) with and without severe excessive daytime sleepiness (EDS).

There is no laboratory test for major depression, although physicians generally request tests for physical conditions that may cause similar symptoms. If depressive disorder is not detected in the ...

Investigating Sunosi as a treatment for MDD patients with and without excessive daytime sleepiness (EDS), a phase 3, proof-of-concept study did not meet its primary endpoint, Axsome said Tuesday.

Major depressive disorder (MDD) is a chronic and recurrent mental condition leading to huge impacts on direct and indirect personal and public medical costs. To overcome such a serious mental ...